Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619696 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL24317818 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL24315779 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL24080124 | 0.82 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL20147889 | 0.79 | SLC6A4 (0.54) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL7235082 | 0.75 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24315771 | 0.75 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL17123796 | 0.74 | SLC6A4 (0.54) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL22839032 | 0.74 | SLC6A4 (0.55) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL26619764 | 0.73 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | SLC6A2 2569/4885SLC6A4 2521/4885SLC6A3 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.